articleThe Lancet OncologySep 21, 2011Closed access

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Universitätsklinikum des Saarlandes · Leipzig University · +14 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

809
total citations
FWCI
27.52
Percentile
100%
References
22
Citations per year

Authors

21

Topics & keywords

Keywords
  • Medicine
  • Rituximab
  • CHOP
  • Diffuse large B-cell lymphoma
  • Open label
  • Internal medicine
  • Oncology
  • Lymphoma
UN Sustainable Development Goals
  • Partnerships for the goals
No related works found for this paper.